Abstract
Background
Preventing ventricular arrhythmias in patients with cardiac amyloidosis is challenging since the amyloid protein deposition in the myocardium may interfere with the normal cardiac electric excitation. Most of these patients succumb to either progressive congestive heart failure, or sudden cardiac death (SCD). Implantable Cardioverter Defibrillator (ICD) offers a near sure means of preventing SCD.
Hypothesis
Myocardial infiltration with amyloid results in elevated defibrillation threshold (DFT). Intra‐operative strategies may fail to lower DFT during implantation.
Methods
We present a case of a 64‐year‐old female who had cardiac amyloidosis, and was successfully treated with an ICD and a subcutaneous array lead system.
Conclusion
A subcutaneous array lead system is useful in reducing the DFT, and can terminate ventricular tachycardia or fibrillation by allowing more energy delivery and efficient defibrillation. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (212.1 KB).
References
- 1. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: A comprehensive review. Arch Intern Med 2006; 166: 1805–1813. [DOI] [PubMed] [Google Scholar]
- 2. Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: Correlation with echocardiographic abnormalities. J Am Coll Cardiol 1984; 3: 107–113. [DOI] [PubMed] [Google Scholar]
- 3. Wright JR, Calkins E. Clinical‐pathologic differentiation of common amyloid syndromes. Medicine (Baltimore) 1981; 60: 429–448. [DOI] [PubMed] [Google Scholar]
- 4. Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light chain associated AL cardiac amyloidosis. Am J Cardiol 1997; 80: 1242–1245. [DOI] [PubMed] [Google Scholar]
- 5. Kühlkamp V, Khalighi K, Dörnberger V, Ziemer G. Single incision and single element Array electrode to lower the defibrillation threshold. Ann Thorac Surg 1997; 64: 1177–1179. [DOI] [PubMed] [Google Scholar]
- 6. Mainigi S, Callans D. How to manage patients with high defibrillation threshold. J Heart Rhythm Soc 2006; 3: 492–495. [DOI] [PubMed] [Google Scholar]
- 7. Kühlkamp V, Dörnberger V, Mewis C, Seipel L. Comparison of the efficacy of a subcutaneous array electrode with a subcutaneous patch electrode, a prospective randomized study. Int J Cardiol 2001; 78: 247–256. [DOI] [PubMed] [Google Scholar]
- 8. Jordaens L, Vertongen P, Van‐Belleghem Y. A subcutaneous lead array for implantable cardioverter defibrillators. PACE 1993; 16: 1429–1432. [DOI] [PubMed] [Google Scholar]
- 9. Higgins SL, Alexander DC, Kuypers CJ, Brewster SA. The subcutaneous array: A new lead adjunct for the transvenous ICD to lower defibrillation threshold. PACE 1995; 18: 1540–1548. [DOI] [PubMed] [Google Scholar]
- 10. Saksena S, Breithardt G, Dorian P, et al. Non‐pharmacological therapy for malignant ventricular arrhythmias: Implantable defibrillator trials. Prog Cardiovasc Dis 1996; 38: 429–444. [DOI] [PubMed] [Google Scholar]
- 11. Kühlkamp V, Dörnberger V, Khalighi K, et al. Effect of a single element subcutaneous array electrode added to a transvenous electrode configuration on the defibrillation field and the defibrillation threshold. Pacing Clin Electrophysiol 21(12): 2596–2605. [DOI] [PubMed] [Google Scholar]
- 12. Lang DJ, Heil JE, Hahn SJ, Lindstrom CC, Derfus DL. Implantable cardioverter defibrillator lead technology: Improved performance and lower defibrillation thresholds. Pacing Clin Electrophysiol 1995; 18: 548–559. [DOI] [PubMed] [Google Scholar]